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ABSTRACT
DISCRIMINATIVE STIMULUS PROPERTIES OF PD149163
By
Candice J. Schuck
Schizophrenia is a life-long debilitating disease that currently affects
approximately 1% of the world population, including 3.2 million Americans.
Currently available pharmacotherapeutics are mainly effective for the positive
symptoms, but are minimally effective for negative symptoms and cognitive
impairment. A promising new class of drugs currently in the experimental phase of
development is called neurotensin analogs and are thought to produce effects similar
to antipsychotic drugs, but the precise mechanisms that lead to the behavioral effect
of neurotensin in the brain is unknown. The current study used a behavioral
procedure called drug discrimination in rats in an attempt to elucidate the mechanisms
that mediate the potential therapeutic effects of neurotensin analogs. The
discriminative stimulus properties of PD149163 were not robust, and after several
changes in training dose, and change to administration route, 6 out of 10 rats met
training criteria to discrimination of 0.0625mg/kg PD149163 dose from vehicle. Full
stimulus generalization occurred to a 0.0312mg/kg and 0.125mg/kg dose of
PD149163. Full stimulus generalization occurred to the D2 receptor-preferring
antagonist haloperidol, at the 0.1mg/kg dose. These findings provide evidence that
the stimulus effects produced through NT1 receptor agonism may be similar to D2
receptor antagonism.
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This work is dedicated to my children, Cassandra, Wyatt, John, and Madeline,
whom I love so very much.
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INTRODUCTION
Schizophrenia
Schizophrenia is a life-long, debilitating disease of the brain that currently
affects over 1% of the world population including more than 3.2 million Americans.
The disease is characterized by positive and negative symptoms and cognitive
impairments. Positive symptoms consist of unusual thoughts or perceptions,
including hallucinations, delusions and severe thought disorganization, and disrupted
motor movement. Negative symptoms represent a reduction in normal emotional and
behavioral states and include flat affect, anhedonia, social withdrawal, and
impoverished speech. Cognitive impairment may consist of disrupted working
memory, attention deficits, and poor executive function.
There are several different forms of schizophrenia, each differing in the type
and level of severity of symptoms. The DSM-IV defines schizophrenia as a disorder
characterized by a deteriorating ability to function in everyday life and by some
combination of hallucinations, delusions, thought disorder, movement disorder and
inappropriate emotional expressions (American Psychiatric Association, 1994).
Cognitive impairment is not included in the DSM-IV, but according to Keefe and
Fenton (2007), patients with schizophrenia score 1.5-2.0 standard deviations below
healthy controls on neurocognitive tasks involving memory, working memory,
attention, problem solving, cognitive processing time and social cognition.
There are many speculations as to the etiology of the schizophrenia. These
include, but are not limited to, multiple convergent factors such as gene expression,
viruses, toxins, nutrition, birth insult and psychological experience involved in the
1

development of the brain from the time of conception to early adulthood (Andreasen,
1999). Studies suggest both genetic and environmental influences, and a large body
of evidence (Meltzer, and Stahl, 1976; Pycock, Kerwin, & Carter, 1980; Seeman,
1988; Carlsson, Waters, Holm-Waters, Tedroff, Nilsson & Carlsson, 2001; Hirvonen,
Van Erp, Huttunen, Aalto, Nagren, Huttunen, Lonnqvist, Hietala, & Cannon, 2005;
Guillin & Laruelle, 2005) suggests that there is an alteration in a number of different
neurotransmitter systems (e.g. dopamine, GABA, glutamate, serotonin) but the exact
cause of schizophrenia remains elusive.
History of schizophrenia
In 1887 German physician Emil Kraepelin first named this disease dementia
praecox related to the rapid cognitive degeneration that was seen beginning in late
teen and early adulthood years. Cognitive degeneration impairs memory, attention,
and the ability to organize behavior appropriately. In 1911, Swiss psychiatrist
Eugene Bleuler renamed this same mental illness schizophrenia, meaning in Greek
SCHIZO (split) and PHRENE (mind). He categorized the symptoms associated with
the disease and coined the terms positive and negative when describing them.
Throughout the late 19th and early 20th century, treatments for people suffering from
schizophrenia focused mainly on calming their abnormal behaviors and episodes of
psychosis. Everything from strait jackets and solitary confinement in padded rooms
to ice baths, induced fever, and insulin or electric shock were used. Additionally, a
neurosurgical procedure that severed the neuronal connections between the frontal
lobes and the rest of the brain began to be used in the late 19th century.

2

In 1888, Gottlieb Burckhardt performed the first psychosurgery of the brain
and presented a paper on his work in 1889 at the Berlin Medical Conference. His
work and writings met criticism from his medical colleagues and eventually led
Burckhardt to discontinue his investigation of cortical lesioning.. Throughout the
years to follow, Burckhardt’s psychosurgery continued to be investigated and his
ideas were revitalized by 1910, developing into a neurosurgical specialty (Manjila,
Rengachary, Xavier, Parker, & Guthikonda, 2008). By 1935 ideas that originated
with Burckhardt had become a neurosurgical procedure called the lobotomy. A
lobotomy consisted of severing the neural connections between the frontal lobes and
the rest of the brain. Physician Walter Freeman refined the lobotomy procedure and
in 1946 began performing transorbital lobotomies in the United States. The
transorbital lobotomy involved utilizing a piece of equipment known as a leucotome,
which resembled an ice pick, to access the brain via the eye socket of the patient. The
procedure allowed for lobotomies to be performed outside of a surgical suite,
therefore making it affordable to those patients he saw as needing it the most but who
could least afford it. The purpose of a lobotomy was to calm psychosis, but all too
frequently patients were left completely incapacitated. Eventually the risks involved
proved to outweigh the benefits and by the early 1970’s the overall use of the
lobotomy procedure had all but ceased. The struggle to improve the lives of patients
with schizophrenia and other mental disorders was ongoing and the search for more
humane and effective measures to treat this disease continued.
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Antipsychotic drugs
The year 1950 brought about the accidental discovery of the first
antipsychotic drug (APD) chlorpromazine. Chlorpromazine is a phenothiazine and
was initially used as an adjunct treatment with anesthetics, to reduce the amount of
anesthesia needed prior to surgical procedures. The drug produced a state of calm
and conscious sedation and eventually was utilized by Henri Lahborit and psychiatric
researchers in France on patients with schizophrenia, effectively alleviating
symptoms of psychosis in those patients it was administered to. Chlorpromazine
began to be used as an APD and led to a significant decrease in the amount of patients
needing to be permanently hospitalized. Between the late 1950’s and early 1980’s the
more than 500,000 patients in psychiatric facilities was reduced to less than 220,000.
The discovery of the beneficial use of chlorpromazine as an APD ignited the
search for additional APDs for the treatment of schizophrenia. The butyrophenones
were the next class of APDs developed. These included drugs such as haloperidol,
perphenazine and fluphenzine, which are considered first generation or typical APDs.
Typical APD’s effectively alleviate positive symptoms in schizophrenia via blockade
of dopamine D2 receptors in the brain. Through blockade of the D2 receptors in the
nigrostriatal dopamine pathway in the brain, typical APD’s also produce undesirable
side effects known as extrapyramidal side effects (EPS). EPS resemble symptoms of
Parkinson’s disease, including muscle rigidity, involuntary motor movements and
tremors. The clinical doses of APDs are directly related to D2 receptor occupancy
and it is noted that a minimum of 50% receptor occupancy is required for clinical
response to APDs. EPS is produced when receptor occupancy reaches 80% or above
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in the nigrostriatal pathway (Kapur, Zipursky, Jones, Remington & Houle, 2000;
Meltzer, 2007). Additionally, long term use of typical APDs may result in a more
serious disorder known as tardive dyskinesia which can persist even after
discontinuation of the medication. Despite the side effects, these medications
provided relief and were used consistently until the early 1990’s at which time a new
class of APDs began to be developed. These new drugs were labeled second
generation or atypical APDs.
Atypical APDs rarely produce EPS and are not only effective in treating the
positive symptoms associated with the schizophrenia, but also reduce the negative
symptoms as well. The behavioral effects of atypical APDs may be produced via
blockade of dopamine D2 receptors and serotonin (5HT2A) receptors in the brain. The
negative symptoms of schizophrenia are thought to result from an imbalance of these
neurochemicals in the mesocortical and mesolimbic dopaminergic pathways in the
brain. It is believed that there is a hyperfunction of dopamine in the mesolimbic
pathway and a hypofunction of dopamine in the mesocortical pathway. These
pathways originate in the ventral tegmental area and project through the limbic
system and prefrontal cortex (Guillin, & Laruelle, 2005). According to a hypothesis
put forth by Meltzer, Matsubara, and Lee (1989), a 3 fold higher affinity for serotonin
(5HT2A) over dopamine (D2) receptors may be indicative of the absence of EPS as
well as improved clinical response, such as effectiveness in treating both positive and
negative symptoms of schizophrenia. Another hypothesis is that atypical APDs are
thought to dissociate much quicker from the D2 receptor than typical APDs. This is
known as the “fast off” effect, which allows for binding of the drug to the D2 receptor
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for just long enough to be effective for positive and negative symptoms but not long
enough to cause EPS. (See Table 1).
Table 1. Receptor binding affinities (expressed a Ki, nM) for PD149163,
neurotensin, and selected antipsychotic drugs
DRUG

NT1

NT2

D2

5-HT2A

PD149163

159

>10,000

>10,000

>10,000

Haloperidol

n/a

n/a

1.4

25

Clozapine

n/a

n/a

150

3.3

Neurotensin

0.25

7

n/a

n/a

Ki vlalues (nM)
(PD149163 data are from Petrie et al. 2004; Haloperidol and Clozapine data are from
Schotte et al. 1996; Neurotensin data are from Pettibone et al. 2001.)
The first atypical APD was clozapine. For a number of years clozapine was
not considered an APD due to its lack of production of EPS-like effects in preclinical
animal models. The production of EPS-like symptoms during trials with animal
models was thought to be a key indicator of a drugs ability to produce APD effects.
Clozapine did not display EPS but it was effective in treating not only the positive
symptoms of schizophrenia, but negative symptoms as well. An estimated 20-60% of
patients with schizophrenia are treatment resistant (Meltzer, & Kostacoglu, 2001;
Miller, McEvoy, & Jeste 2006) and although 40-60% of the treatment resistant
patients are also resistant to clozapine, it is considered the gold standard drug for use
in patients with treatment resistant schizophrenia. Although clozapine was highly
effective in treating schizophrenia it had a very dangerous side effect called
agranulocytosis. Agranulocytosis involves the loss of the white blood cells that fight
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off infection and can be deadly if the patient’s blood count is not monitored very
closely. In 1976, 17 of approximately 3,000 patients in Finland suffered from
agranulocytosis after taking clozapine, 8 of whom had fatal reaction. This led to a
full investigation and brief halt to the use of clozapine. With the reinstatemen of
clozapine as an APD came the requirement of weekly blood count monitoring in
effort to prevent this devastating side effect (Idanpaan-Heikkila, Alhava, Olkinuora,
& Palva, 1977).
Over the last two decades other atypical APDs have been developed, such as
risperidone, olanzapine, quetiapine, sertindole and ziprasidone. These drugs are
thought to be equally as effective as clozapine and rarely produce EPS or
agranulocytosis, but may cause metabolic disturbances associated with diabetes
mellitus and hypercholesterolemia. They may also produce a cardiac abnormality
called QT interval prolongation, where the length of time in the heartbeat is longer.
Generally this is not a severe complication unless it progresses into a condition called
torsades de pointes which causes sudden cardiac arrest ultimately causing death.
A large clinical trial study entitled CATIE (Clinical Antipsychotic Trials of
Intervention Effectiveness) funded by the National Institute of Mental Health
compared and contrasted both efficacy and side effects of 1 typical (perphenazine)
and 4 atypical (olanzapine, quetiapine, risperidone and ziprasidone) APDs
(Lieberman, Stroup, McEvoy, Swartz, Rosenheck, Perkins, Keefe, Davis, Davis,
Lebowitz, Severe, & Hsiao, 2005). A total of 1493 patients suffering from
schizophrenia, from 57 different clinical locations in 24 states, participated in the
CATIE study. The sampling of patients included participants of academic and mental
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health treatment facilities and were representative of the population being
investigated. The objective of the study was to investigate ways to maximize the
benefits and minimize the side effects in use of APDs.
A major issue with APD use is non-compliance by the patient. Patients
generally will not comply with medication regime related to the severity of side
effects and/or lack of significant improvement of symptoms. Poor medication
compliance leads to poor control of symptoms and relapse. Throughout the course of
the CATIE study, over 74% of the participants were switched to a different
medication than the one they were started on, related to intolerable side effects.
Those patients who were started on olanzapine most consistently followed the
medication regime and had less frequent instances involving hospitalization but were
subject to metabolic side effects that were not as severe with the other APDs tested.
Overall, the older typical APD perphenazine was just as effective as the new atypicals
and all of the atypicals were comparable to one another (Lieberman, et al., 2005;
Keefe, Palmer, Capuano, Rosenheck, & Lieberman, 2007). Considering cost,
effectiveness and tolerability, this study provided comprehensive information in
regards to the comparison of different APDs that are currently on the market for
schizophrenia, giving patients and doctor’s information needed to make appropriate
decisions regarding the use of APDs.
The main goal in developing APDs is to provide therapeutics that improve the
patients overall ability to function (i.e. physically, emotionally and cognitively) on a
daily basis. For the most part, APDs currently on the market are primarily effective
for positive symptoms and have less of an effect for the negative symptoms and
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cognitive impairment. Thus, there continues to be a need for APDs that not only
improve positive and negative symptoms, but cognitive impairments as well.
Dopamine
Dopamine (DA) is a catecholamine neurotransmitter which may mediate the
efficacy of all APDs. There are currently 5 known DA receptors. They are divided
into two families, the D1 receptor family (D1 and D5) and the D2 receptor family (D2,
D3 and D4). All DA receptors are G-protein coupled receptors that are located both
on DA neurons (autoreceptors, D2 and D3) and on postsynaptic cells, including those
which are cholinergic, GABA-ergic, glutamatergic, peptidergic and serotonergic (all
subtypes, D1-D5). 80-90% of DA neurons are located in the mid brain and project
throughout the brain along the nigrostriatal, mesolimbic and mesocortical pathways
(see Binder, Kinkead, Owens, & Nemeroff, 2001, for review). The DA midbrain
nuclei consist of the substantia nigra (SN), ventral tegmental area (VTA) and the
retrorubral field. The nigrostriatal dopaminergic pathway begins in the SN and
projects to the neostriatum (caudate nucleus and putamen). This area is involved in
motor function. The mesolimbic dopaminergic pathway begins in the VTA and
projects to several areas of the limbic system which is involved in reward and
integration of time and space. The mesocortical pathway also begins in the VTA but
projects out to the motor, premotor and prefrontal cortices, areas which are involved
in working memory and executive function.
Neurotensin
Recent research has focused more closely on other neurochemicals that
interact with the dopaminergic systems within the brain, such as neurotensin (Binder,
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et al. 2001; McMahon, Boules, Warrington, & Richelson, 2002; Dobner, 2005).
Neurotensin is a neuropeptide that was first isolated by Carraway and Leeman in
1973. Neuropeptides act as chemical mediators in neuron to neuron communication,
integrating complex behaviors. Peptides are located in vesicles in axon terminals and
the cell bodies for neurotensin are co localized in several areas of the brain with
dopamine. At least three neurotensin receptors have been discovered thus far.
Neurotensin has the highest affinity for NT1, a 10 fold less affinity for NT2 and 1,000
fold less affinity for NT3, which is also the least studied. When neurotensin binds to
the NT1 receptor, it has been shown to act through several different mechanisms
which inhibit dopamine release and decrease D2 receptor agonist binding affinity (see
Binder et al. 2001 for review).
Dopamine and neurotensin interactions
Neurotensin co localizes with DA throughout the brain. 80-90% of
neurotensin receptors (NTR) are expressed on DA neurons and most DA neurons in
the ventral tegmental area and substantia nigra have NTR, especially NT1. The
mechanism of action by which NT affects DA, results from NT binding to NT1.
When NT binds it may regulate gene expression, exhibit receptor/receptor allosteric
interactions by activating 2nd messenger systems or alter cell firing and ion channels.
These actions in turn inhibit D2 receptor binding. Furthermore, activating NT1 in the
midbrain DA neurons may cause cells to depolarize which creates opposition of DA
agonists. It can also induce auto inhibition of the cells firing rate and alter the activity
of DA neurons (Binder et al., 2001).
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In patients with schizophrenia who displayed a greater degree of psychotic
symptoms, neurotensin levels in cerebrospinal fluid were significantly decreased.
With the use of APDs, neurotensin levels were brought back to a level comparable to
those of normal controls (Wilderlov, Lindstrom, Besev, Mansberg, Nemeroff, Breese,
Kizer, & Prange, 1982). Additionally, patients with low cerebral spinal fluid
concentrations of neurotensin had a greater degree of thought disorder, delusions and
hallucinations, behavioral disorganization and impaired functioning. Sharma,
Janicak, Bissette, and Nemeroff (1997) performed a study which compared level of
psychopathological behavior to levels of neurotensin in cerebral spinal fluid of 42
participants with schizophrenia (N=29) or schizoaffective disorder (N=13) prior to
treatment with an APD. Following four weeks of treatment with APDs, 18 of the
subjects (schizophrenia N=14, schizoaffective disorder N=4) agreed to a second
cerebral spinal fluid analysis. Pretreatment psychopathology was significantly higher
for those subjects with the lowest levels of neurotensin in CSF. In addition, they
found that a decrease in negative symptoms and psychopathological behaviors was
correlated to higher levels of neurotensin in CSF. Findings such as these suggest that
neurotensin is somehow involved in the etiology of the chemical imbalance in
schizophrenia and has behavioral, physiological and pathological significance.
The possible influence that dopamine and neurotensin systems may have on
one another has initiated many studies that have implicated neurotensin in the
pathophysiology of certain central nervous system disorders, including schizophrenia
(McMahon et al., 2002; Seutin, 2005; Dobner, 2005). Several laboratory tests using
animal models have shown that neurotensin and neurotensin analogs produce effects
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similar to that of antipsychotic drugs (Tanganelli, O’Conner, Ferraro, Bianchi, Beani,
Ungerstedt, & Fuxe, 1994; Meltzer, & McGurk, 1999; Austin, 2000; Hamid, Hyde,
Ehan, Wolf, Herman, Nemeroff, & Kleinman, 2002; Feifel, Melendez, & Shilling,
2003; Petrie, Bubser, Casey, Davis, Roth, & Deutch, 2004; Stowe, Landry, Tang,
Owens, Kinkead, & Nemeroff, 2005; Azmi, Norman, Spicer, & Bennett, 2006; Prus,
Huang, Li, Dai, & Meltzer, 2007; Norman, Beckett, Spicer, Ashton, Langlois, &
Bennett, 2008). Tanganelli et al. (1994) showed that microinfusion of neurotensin
facilitated GABA release and was associated with a decrease in dopamine in the rat
nucleus accumbens while results from a study by Stowe et al. (2005) investigating the
electrophysiological effects of neurotensin on spontaneously active neurons in the rat
nucleus accumbens indicate that neurotensin does in fact mediate therapeutic efffects
of APDs. Azmi et al. (2006) was able to reverse the effects of memory disruptive
scopolomine with the use of PD149163 in a novel object recognition task and Feifel
et al. (2003) was able to block disruption of prepulse inhibition that was produced by
a serotonin (5HT2A) agonist with the systemic administration of the neurotensin
agonist PD149163. In addition, Petrie et al. (2004) investigated FOS expression in
the prefrontal cortex of rats and found that PD149163 increased the FOS expression,
suggesting that neurotensin plays a role in the activation of interneurons in the
prefrontal cortex. These studies support the hypothesis that neurotensin analogs
improve neurochemical levels in ways that may offer superior efficacy for treating
patients with schizophrenia.
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PD149163, a novel analog of neurotensin
When given systemically neurotensin is unable to penetrate the blood-brain
barrier. In order to investigate neurotensin thoroughly researchers needed to develop
a neurotensin mimetic (neurotensin analog) which would cross the blood-brain barrier
(Binder et al., 2001; McMahon et al., 2002; Dobner, 2005). Several neurotensin
analogs are now available and are currently in the experimental phase of
development.
The experimental compound PD149163 is a neurotensin analog. Studies
have been done that support the hypothesis that neurotensin interacts with dopamine
and has effects similar to those of APDs. Feifel, Melendez and Shilling (2004) used a
animal model called pre-pulse inhibition, which is used for screening drugs for APD
effects, to test the effects of the typical APD haloperidol, the atypical APD clozapine
and PD149163 on sensorimotor gating. The study used Brattleboro rats which have a
genetic mutation that creates a deficit in pre-pulse inhibition (PPI) that is comparable
to people with schizophrenia. They found that with acute administration of all three
drugs, haloperidol 0.05mg/kg had no effect on PPI with acute administration but had
effect with chronic administration is a previous study by the same researchers.
Clozapine 10mg/kg and 15mg/kg, and PD149163 1.0, 3.0 and 5.0mg/kg doses all
were effective in reversing the PPI deficit in these genetically mutant rats. This
evidence supports the hypothesis that the neurotensin analog PD149163 has atypical
APD-like properties. In contrast, Norman et al. (2008) completed another behavioral
model used for screening APDs that involves amphetamine induced hyperlocomotion.
PD149163 was administered centrally and subchronically for 7 days and chronically
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for 21 days. Previous studies had shown attenuation of amphetamine induced
hyperlocomotion with acute administration, but Normans 2008 study showed no
effect on amphetamine induced hyperlocomotion after 7 days administration of
PD149163 and potentiation after 21 days administration. These findings are
indicative of the need to further elucidate the behavioral effects of PD149163. A
number of studies have been done to investigate the putative APD effects of
PD149163, but none have yet been done to investigate the receptor properties that
mediate the behavioral effects of neurotensin or neurotensin analogs, including
PD149163. One way researchers have of determining how the effects of certain
drugs in the brain produce their behavioral effects is by using an animal model called
the drug discrimination (DD) task.
Drug Discrimination
The drug discrimination (DD) task and training procedure is analogous to
procedures that are used to establish sensory discriminations (e.g., turn right when the
cue light is on and left when it is off) except that the differential sensory conditions
are replaced by drug conditions which are said to have stimulus effects. In rodent
models the subject is said to have learned to discriminate and the drug is said to be
discriminable when the response appropriate to the current drug state is reliably
performed. Utilizing this task allows researchers to compare new experimental drugs
with other known APDs to determine what properties they hold and what their
functional mechanisms are.
Drug discrimination is used in preclinical development of APDs to evaluate
pharmacological mechanisms that mediate discriminative stimulus properties and the
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distinguishable differences in typical and atypical APDs. Numerous studies have
been done using the DD task (Stewart, 1962, Colpaert, Niemegeers, & Janssen, 1976;
McElroy, Stimmel, & O’Donnell, 1989; Prus, Baker, & Meltzer, 2004; Prus, Philibin,
Pehrson, Stephans, Cooper, Wise, & Porter, 2005; Porter, & Prus, 2009) and several
APDs (chlorpromazine, haloperidol, clozapine, olanxapine, quetiapine, ziprasidone)
over the last 40 years.
Chlorpromazine was the first APD to be successfully discriminated by
animals by Stewart in 1962 in a shock avoidance task, and haloperidol was then
found to be discriminable in a two lever operant discrimination task with food reward
by Colpaert et al. (1976) and McElroy et al.(1989). Colpaert et al. (1976) reported
much difficulty training with haloperidol 0.04mg/kg, requiring in excess of 80
training sessions to establish the discrimination. Typically, 30-40 training sessions
enables accurate discriminative responding in the DD task. The study done by
McElroy et al. (1989) established discrimination over a mean of 45 training sessions
for haloperidol 0.05mg/kg. Although Colpaert did not test for generalization,
McElroy did and found that chlorpromazine fully generalized to haloperidol with
83% drug lever responding. Both haloperidol and chlorpromazine are D2 receptorpreferring antagonists, so stimulus generalization between these two drugs shows
evidence of D2 antagonism. Additional support that the discriminative stimulus
properties of haloperidol include antagonism of dopamine receptors was obtained by
testing with cocaine and amphetamine which are dopamine agonists. Haloperidol’s
discriminative stimulus was completely blocked by these drugs.
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The atypical APD clozapine was first established as a training drug in DD by
Goas and Boston (1978). Clozapine displays robust discrimination stimulus
properties time and again and has since become the prototypical or gold standard
atypical APD by which other APDs and potential APDs are compared, to evaluate for
putative APD properties and receptors mechanism of action (see Porter and Prus,
2009 for review). According to the literature, few APDs have been used as training
drugs in the drug discrimination paradigm, but existing studies have provided
valuable information about the differences and similarities between typical and
atypical APDs. By using APDs as training drugs in the drug discrimination paradigm
and testing stimulus generalization between the training drug and other compounds,
we can draw an inference about what mechanistic properties a new compound or
existing APD may have.
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RATIONALE
Drug discrimination is one of the most informative methods used by
researchers for investigating behavioral and neuropharmacological effects of drugs.
By training an animal to identify the characteristic effect of a drug (DS) we can
measure the effects in a precise, reliable and quantifiable manner. We can compare
drugs already investigated and FDA approved with experimental compounds to
investigate the putative APD effects and elucidate the receptor mechanisms involved
in the drugs action.
Recent studies using animal models have lent support to the hypothesis that
neurotensin analogs produce behavioral effects similar to APDs, yet the precise
receptor mechanisms responsible for these effects are unknown. Drug discrimination
was therefore used in the current study in an attempt to evaluate and clarify the
receptor mechanisms involved in the discriminative stimulus effects of the
neurotensin analog PD149163.
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METHODS
Subjects
Ten male Sprague Dawley rats (Charles River, Portage, Michigan, USA)
obtained at approximately 90 days old were used for this study. The subjects were
housed in the rodent colony located at Northern Michigan University, Marquette,
Michigan. The rodent colony was kept on a 12 hour light/dark schedule with lights
on at 0700. Temperature and humidity were held at a constant and subjects were
housed individually in transparent polysulfone flat-bottom cages with free access to
water. Due to the fact that the subjects would be working for food reward during
training sessions food access was restricted to maintain 85% of each subject’s freefeeding weight. All procedures were approved in advance by the Northern Michigan
University Institutional Animal Care and Use Committee (protocol 113) and were
consistent with the Guide for the Care and Use of Laboratory Animals (National
Research Council, 1996).
Apparatus
Six rat operant chambers equipped with two retractable levers, a food
receptacle, 45mg pellet dispenser and a 28V light were used (Med-Associates Inc., St.
Albans, Vermont, USA). The levers were located equidistantly on either side of the
food pellet receptacle. The chambers were housed in sound-attenuating cubicles with
fans for ventilation and masking noise. The chambers were controlled by and data
were recorded using, Med-PC version 4 (Med-Associates Inc.)
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Drugs
PD149163 (NIMH Chemical Synthesis and Drug Supply Program, National
Institute of Mental Health, Bethesda, Maryland, USA), and haloperidol HCl (Tocris,
Ellisville, Missouri, USA) were in salt form and administered in 1ml/kg volume.
PD149163 was dissolved in sterile water and haloperidol HCl was dissolved in sterile
water with a few drops of lactic acid. The number and range of doses were
determined based upon behaviorally effective doses that had previously been used in
other research studies involving these drugs. The number and range of doses were
additionally tested in order to form a dose-effect curve that began at a dose with no
effect and ended with a dose with full effect or highly suppressed response rate.
Drugs were injected in a 1ml/kg volume either subcutaneously (SC) or
intraperitoneally (IP) 30 minutes prior to a session.
Drug Discrimination Training
There were several stages to the training process in the drug discrimination
procedure: lever press training, fixed ratio training, errorless training and drug
discrimination training. Test sessions began after drug discrimination training was
complete. Only one training or test session was completed each day (see figure 1).
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Figure 1. Steps to Drug Discrimination Training.

Subjects were initially trained to lever press using a fixed-ratio (FR) 1
schedule. Training began with the saline appropriate lever. Lever assignment was
counterbalanced for left or right positioning within the group of subjects. After lever
press training the FR was gradually increased, based on performance, until subjects
responded on a FR20 schedule. Once trained to lever press on the FR20 schedule, 5
consecutive errorless daily 20 minute training sessions of saline and then the training
dose of PD14916 (see RESULTS below for the training dose used) were conducted
with only the condition-appropriate lever present. Following errorless training
sessions, two-lever drug discrimination training began, with saline (S) and PD149163
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(D) training days assigned based on a single-double alternation pattern (i.e.,
SDSSDSDDS etc.). During two-lever training, every lever press reset the FR20
counter for the opposite lever. Subjects were tested once the following criteria were
met for 5 out of 6 consecutive training sessions: 1) first FR20 occurring on the
condition-appropriate lever, 2) 80% or greater condition-appropriate responding
during the first FR20, 3) 80% or greater condition-appropriate responding for the total
session, and 4) at least 0.1 responses per second for the total session.
Before every test session, subjects had to meet the above four criteria for both
a saline and a PD149163 training session. Test sessions ended after an FR20
occurred on either lever and no food pellet reward was delivered. Otherwise, the
session ended after 20 minutes. As with training sessions, every lever press reset the
FR20 counter on the opposite lever.
Data Analysis
Percent PD149163-lever responding was expressed as a percentage based on
the number of PD149163-appropriate responses emitted divided by the total number
of PD149163 and saline-appropriate responses emitted. In order to be included in the
percent PD149163-lever responding calculation, rats were required to emit at least 10
responses during the test session. Percent PD149163-lever responding and responses
per second were reported as means +/- the standard error of the mean (SEM). Full
stimulus generalization from the PD149163 discriminative stimulus was defined as
80% or greater PD149163-appropriate responding, based on the criteria used in
training sessions. No stimulus generalization was defined as 20% or less PD149163appropriate responding, and partial stimulus generalization was defined as 20-80%
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PD149163-appropriate responding. Statistically significant differences in response
rates across doses and control points were determined using a repeated measures one
way analysis of variance (ANOVA). Statistically significant differences were
followed by a Dunnett’s post hoc test to compare response rates for each dose to
saline control. Regression methods were used to calculate the ED50 dose (+/- 95%
confidence intervals [CI]) for percent PD149163-appropriate responding for drugs
that produced full stimulus generalization. All analyses were conducted using
GraphPad Prism for Windows, version 5.02 (GraphPad Sofware, San Diego,
California, USA).
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RESULTS
After completion of magazine training (2 sessions) each subject completed 5
sessions of lever press training. Once subjects learned to lever press on a fixed-ratio
(FR) of one the FR was gradually increased to reach an FR20. Subjects 1-8 completed
FR20 training in 8 sessions, subject 9 took 29 sessions and subject 10 took 9sessions.
Following FR training subjects then completed 5 sessions of errorless training in
which only the saline-appropriate lever was present. After 5 saline-appropriate lever
errorless training sessions were complete, 5 errorless training sessions with
PD149163-appropriate lever present were completed. The beginning dose of
PD149163, 0.5mg/kg, was administered via intraperitoneal injection (IP) 30 minutes
prior to training session. A reduction in responding was seen with this dose and after
4 sessions the training drug dose was decreased to 0.25mg/kg via IP injection. Each
subject (with the exception of 9) completed 7-9 sessions alternating with saline as not
to exceed 3 drug days in a row at the 0.25mg/kg IP dose. This dose also was found to
create significant response rate suppression. The drug dose was again decreased.
Subjects 1, 3, and 10 were trained for 4-6 sessions at the 0.125mg/kg IP dose before
beginning 2-lever drug discrimination training at a dose of 0.1mg/kg IP and all other
subjects began 2-lever drug discrimination training at this time on 0.1mg/kg IP. The
PD149163 0.1mg/kg training dose was utilized for an additional 5 sessions for
subjects 1-8 and 2 sessions for 9 and 10 before re-evaluation of data. The training
dose was at that time (approximately trial 32 of DD training across subjects except
#9) decreased to 0.05mg/kg IP. Response rates improved to a range acceptable to set
criteria. This dose was used and subject responses evaluated over approximately 30
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sessions (60, including double single alternating design with saline) but accuracy was
not consistently above 80% for first fixed ratio (FFR). Criteria set calls for 80% or
greater FFR accuracy for 5 of 6 consecutive training sessions. Training dose was
then changed to PD149163 0.25mg/kg, and route changed to subcutaneous (SC)
injection. A total of 8 drug training sessions were conducted at this dose. Response
rate suppression was seen once again. Dose was then decreased to 0.125 mg/kg SC.
After 15-19 training sessions 6 of the 10 subjects were able to finally meet criteria for
stimulus generalization testing. The remaining 4 animals (1, 2, 3 and 5) continued to
train on the 0.125mg/kg SC dose for a total of 32 additional drug training sessions
before the dose was decreased once again to 0.0625mg/kg SC for all subjects,
including the 6 subjects who met criteria at an average of 121 total saline/drug drug
discrimination training sessions. Subjects 1, 2, 3 and 5 needed to have the training
drug dose reduced again after 3 drug training sessions at PD 0.0625mg/kg to PD
0.0312mg/kg. Subjects 1,2 and 3 were then able to meet set criteria with an average
of 212 total DD training sessions. Although these subjects were finally able to
progress to stimulus generalization testing they were unable to complete the dose
response curve for the training drug and their data are therefore excluded from the
studies final analysis. Subject 5 never met training criteria and was excluded from
the study completely after a total of 312 DD training sessions. (For review, see Table
2)
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Table 2. Drug discrimination training trials to meet criteria (values in each cell
equal the number of sessions conducted for that condition)
SUBJECT

1

2

3

4

5

6

7

8

9

10

FR TRAIN

8

8

8

8

8

8

8

8

29

9

ERRORLESS SALINE

5

5

5

5

5

5

5

5

5

5

PD0.5mg/kg IP

4

4

4

4

4

4

4

4

PD0.25mg/kg IP

8

7

9

7

7

7

7

7

PD0.125mg/kg IP

6

ERRORLESS DRUG
TRAINING/DOSES

8

5

4

DRUG DISCRIMINATION
TRAINING/DOSES
PD0.1mg/kg IP

5

5

5

5

5

5

5

5

2

2

PD0.05mg/kg IP

30

31

30

31

30

31

27

31

30

27

PD0.25mg/kg SC

8

8

8

8

8

8

8

8

8

8

PD0.125mg/kg SC

32

31

32

16

32

19

15

16

17

16

PD0.0312mg/kg SC

17

17

17

17

PD0.0625mg/kg SC

3

3

3

3

95

98

58

55

55

33

43

TOTAL SALINE SESSIONS 80
TRIALS TO CRITERIA

59

195 210 233 130

132 121 126 110 108

Stimulus generalization grouped testing results for PD149163 are shown in
figure 2. PD149163 produced full stimulus generalization to itself (80% PD-drug
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lever responding or greater) at the 0.0625mg/kg SC training dose as well as the
0.125mg/kg SC dose. (ED50= 0.041mg/kg, 95% confidence-interval (CI)= 0.0300.054mg/kg). Although a significant suppression in response rates (relative to Saline)
occurred at both of these doses (F[5,25]= 7.63, p<0.001) (see figure 3). No
substitution was seen at PD149163 0.0156mg/kg or 0.0312mg/kg doses and partial
substitution was seen in 3 subjects for the 0.25mg/kg SC dose although response rates
were greatly suppressed at this dose with 3 subjects having no response at all. (See
figures 4 and 5 for individual results).

PD149163
% Drug Lever Responding

100

N=6

(5)

80
60

(3)

40
20
0
SAL

PD

0.016 0.031 0.063 0.13

Dose (mg/kg)

Figure 2. Percent drug lever responding for PD149163
26

0.25

PD149163

Responses Per Second

1.2

N=6

1.0
0.8

(5)
(5)

0.6

**

0.4

**
***

0.2
0.0
SAL

PD

0.016 0.031 0.063 0.13

Dose (mg/kg)
Figure 3. Responses per second for PD149163

27

0.25

PD149163
4
6
7
8
9
10

% Drug Lever Responding

100
80
60
40
20
0

SAL

PD

0.0156 0.0312 0.0625 0.125

0.25

Dose (mg/kg)
Figure 4. Percent drug lever responding for PD149163 for individual subjects
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Figure 5. Responses per second for PD149163 for individual subjects
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Stimulus generalization testing to D2 receptor preferring antagonist and
typical APD haloperidol was completed following the dose response curve for
PD149163. Group results are shown in figure 6. Haloperidol was tested at the
following four doses, 0.025, 0.05, 0.1 and 0.2mg/kg SC. Full stimulus generalization
occurred at the 0.1mg/kg SC dose of haloperidol. (ED50= 0.051mg/kg, 95% CI=
0.034-0.077mg/kg). Partial generalization occurred to a dose of 0.05mg/kg and no
stimulus generalization was seen at the 0.025mg/kg SC dose. Figure 7 shows
response rates for haloperidol as a function of dose. Response rates were
significantly suppressed compared to those from saline, across all doses except
0.025mg/kg SC (F[4,16]= 3.153, p<0.01). Haloperidol 0.2mg/kg proved to be too
behaviorally disruptive to obtain sufficient test results. (See figures 8 and 9 for
individual results)
It should be noted that through casual observation, at approximately three
minutes post injection of training drug PD149163, subjects consistently displayed a
repetitive, purposeless digging behavior that would last approximately 4-5 minutes.
Following this behavior the subjects would transition into a sedated state. With doses
above 0.0625mg/kg of the training drug PD149163 the sedation persisted throughout
training/test sessions.
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Figure 6. Percent drug lever responding for haloperidol
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Figure 7. Responses per second for haloperidol
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Figure 8. Percent drug lever responding for haloperidol for individual subjects
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Figure 9. Responses per second for haloperidol for individual subjects
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DISCUSSION
The present study utilized the drug discrimination paradigm in an attempt to
assess the discriminative stimulus properties of PD149163. The discriminative
stimulus properties of PD149163 were not robust and after several changes in training
drug dose and administration route, 6 out of 10 subjects finally met training criteria to
discriminate a PD149163 0.0625mg/kg dose from saline. Overall training took a
mean of 121 twenty minute training sessions with one training session per day. Full
stimulus generalization occurred to a 0.0625mg/kg and 0.125mg/kg dose of
PD149163. Full stimulus generalization to the D2 receptor-preferring antagonist and
typical APD haloperidol was shown at the 0.1mg/kg haloperidol dose but with
significant rate response reduction.
Since DD has never been established with neurotensin or a neurotensin analog,
doses of PD149163 that were used in other studies were used as a guide when deciding
upon a training dose for the current study. Feifel et al.(2004) was able to use 1.0, 3.0 and
5.0 mg/kg doses of PD149163 without behavioral disruption and Shilling and Feifel
(2008) used 1.5 and 0.5mg/kg doses effectively. The current study began training at the
PD149163 0.5mg/kg training dose. This dose proved to have severe rate suppressant
effects, leading to a progressive systematic decrease in doses used for training these rats.
These disruptions in response rates in DD are not uncommon for APDs. For example,
Goudie and Smith (2002) established the atypical APD quetiapine as a discriminative
stimulus, but only at a dose that significantly suppressed response rates compared to
vehicle. Furthermore, Porter, McCallum, Varvel, and Vann (2000) established a 10.0
mg/kg dose of the atypical APD clozapine as a discriminative stimulus, but only have
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repeated administration of this dose to invoke tolerance. Similar effects have been
reported for a 5.0 mg/kg clozapine training dose by Prus et al (2005). These effects are
not unlike those seen clinically, although tolerance generally develops to the sedating
effects of APDs after several weeks. For 6 of the subjects in the present study, it took an
average of 121 training sessions, several changes in dose and one change in route, in
order to meet set criteria for drug discrimination. The dose for these 6 subjects was
PD149163 0.0625mg/kg. Although this is the lowest dose used thus far in published
literature involving PD149163, this dose proved to be too potent still for the remaining 4
subjects in the current study. Although the remaining 4 subjects continued on at a lower
dose, they were still unable to maintain criteria after excessive trials, with one subject
being eliminated from the study completely after over 300 training sessions.
The drug discrimination paradigm has been used for decades as a preclinical
investigative tool in studying psychoactive drugs. Literature dating back to the early
70's has reported difficulty establishing discriminative stimulus properties of typical
APDs (Colpaert et al. 1976; McElroy, et al. 1989). Colpaert et al. (1976) reported
discrimination of the typical APD haloperidol at a dose of 0.04mg/kg by rats but with
much difficulty, requiring over 80 sessions to drug discrimination training. McElroy
et al. (1989) was able to establish discrimination with haloperidol at a 0.04mg/kg
dose with lengthly training and then show stimulus generalization to chlorpromazine,
but that was the only drug tested for stimulus generalization in that study. Both drugs
are D2 receptor- preferring antagonists and typical APDs. In the current study not
only was it very difficult to establish the discriminative stimulus cue for PD149163,
full stimulus generalization to the typical APD haloperidol was shown, suggesting
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that the neurotensin analog PD149163 holds similar stimulus properties to D2
receptor antagonists. This is curious considering the amount of research that gives
support to the notion that PD149163 is more like an atypical APD, which are known
to not only exhibit there behavioral effects through blockade of D2 receptors, but
through 5-HT2A receptors as well.
The current findings of stimulus generalization from PD149163 to
haloperidol suggest that the discriminative stimulus effects of PD149163 may be
produced by indirect inhibition of D2 receptor function. Neurotensin NT1 receptor
activation has been shown to decrease the affinity for dopamine to the D2 receptors,
which functionally may act like a D2 receptor antagonist. This may be the basis for
stimulus generalization to haloperidol, which is a highly selective D2 receptor
antagonist. Yet, unlike D2 receptor antagonists, PD149163 appears to be completely
devoid of EPS liability. In animals, doses of PD149163 as high as 1.0 mg/kg (Fiefel
et al. 2004) and 8.0 mg/kg (Holly, Ebrecht, and Prus, submitted) have entirely failed
to produce catalepsy in rats. Similarly, the neurotensin analog NT69L not only fails
to elicit catalepsy in rats, but also prevented haloperidol-induced catalepsy in rats
(Cusack, Boules, Tyler, Fauq, McCormick, & Richelson, 2000). Thus, while
PD149163 so far appears to share discriminative stimulus effects with haloperidol,
PD149163 does not appear to exhibit a typical APD-like behavioral profile.
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CONCLUSIONS
The present study provides the first characterization of the discriminative
stimulus properties of a neurotensin analog. Based the present findings, the
discriminative stimulus properties of PD149163 appear similar to those elicited by D2
receptor blockade. This however, is inconsistent with the atypical APD-like
properties shown in other animal models. Thus, further evaluation of the
discriminative stimulus properties of PD149163 and other neurotensin analogs is
warranted. An important next step should be to further evaluate effective training
doses in order to identify a dose that elicits a more robust discriminative stimulus.
Future directions of this research should include 1) stimulus generalization testing
with a negative control, such as the D2 agonist apomorphine, 2) stimulus
generalization testing to other neurotensin analogs, 3) blockade of the discriminative
stimulus effects of PD149163 by a NT receptor antagonist, and 4) stimulus
generalization testing to atypical APDs, and 5) stimulus generalization testing to
ligands that are selective for receptors that atypical APDs bind to (e.g., 5-HT2A
receptors). Methodological variations might also be pursued, such as using a variable
interval reinforcement schedule.
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